Entry

D00535                      Drug

Name

Vigabatrin (JAN/USP/INN);
Sabril (TN)

Product

SABRIL (Lundbeck Pharmaceuticals LLC), SABRIL (Lundbeck Pharmaceuticals LLC)

Generic

VIGABATRIN (Accord Healthcare), VIGABATRIN (Actavis Pharma), VIGABATRIN (Actavis Pharma), VIGABATRIN (Amneal Pharmaceuticals NY LLC), VIGABATRIN (Amneal Pharmaceuticals NY LLC), VIGABATRIN (Ascend Laboratories), VIGADRONE (Aucta Pharmaceuticals), VIGADRONE (Aucta Pharmaceuticals), VIGABATRIN (Aurobindo Pharma Limited), VIGABATRIN (Aurobindo Pharma Limited), VIGABATRIN (Biocon Pharma), VIGABATRIN (Cadila Healthcare Limited), VIGABATRIN FOR ORAL SOLUTION (Camber Pharmaceuticals), VIGABATRIN (Cipla USA), VIGABATRIN (Dr. Reddy's Laboratories Inc.,), VIGABATRIN (Dr. Reddy's Laboratories Inc.,), VIGABATRIN (Elite Laboratories), VIGABATRIN FOR ORAL SOLUTION USP, 500 MG (Granules Pharmaceuticals), VIGABATRIN FOR ORAL SOLUTION USP, 500 MG (Hikma Pharmaceuticals USA), VIGABATRIN (Lupin Pharmaceuticals), VIGABATRIN (Padagis US LLC), VIGABATRIN (Padagis US LLC), VIGABATRIN (Par Pharmaceutical), VIGADRONE (Upsher-Smith Laboratories), VIGABATRIN (Zydus Pharmaceuticals (USA))

Formula

C6H11NO2

Exact mass

129.079

Mol weight

129.157

Structure

Simcomp

Class

Neuropsychiatric agent
DG03199 Antiepileptic agent
DG02037 GABA mimetic antiepileptic

Remark

Same as:

C07500

Therapeutic category:

1139

ATC code:

N03AG04

Product:

D00535<JP/US>

Efficacy

Anticonvulsant, Antiepileptic

Disease

Infantile spasms [DS:H01460]

Comment

Fatty acid derivative

Target

ABAT [HSA:18] [KO:K13524]

Pathway

hsa04727

GABAergic synapse

Interaction

Structure map

map07033

Anticonvulsants

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
  N03 ANTIEPILEPTICS
   N03A ANTIEPILEPTICS
    N03AG Fatty acid derivatives
     N03AG04 Vigabatrin
      D00535  Vigabatrin (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Anticonvulsants
  Gamma-aminobutyric Acid (GABA) Augmenting Agents
   GABA Agents, Other
    Vigabatrin
     D00535  Vigabatrin (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1  Agents affecting nervous system and sensory organs
  11  Agents affecting central nervous system
   113  Antiepileptics
    1139  Others
     D00535  Vigabatrin (JAN/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
  DG03199  Antiepileptic agent
   DG02037  GABA mimetic antiepileptic
    D00535  Vigabatrin
Drug classes [BR:br08332]
Neuropsychiatric agent
  DG03199  Antiepileptic agent
   D00535  Vigabatrin
Target-based classification of drugs [BR:br08310]
Enzymes
  Transferases (EC2)
   Aminotransferase
    ABAT
     D00535  Vigabatrin (JAN/USP/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D00535
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D00535
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D00535
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D00535

Other DBs

CAS:	60643-86-9

PubChem:

7847601

ChEBI:

63638

LigandBox:

D00535

NIKKAJI:

J82.341D

KCF data

ATOM        9
            1   C1c C    17.4113  -16.5555
            2   C1b C    18.6260  -15.8548
            3   N1a N    16.1967  -15.8607
            4   C2b C    17.4172  -17.9570
            5   C1b C    19.8406  -16.5438
            6   C6a C    21.0553  -15.8490
            7   O6a O    22.2641  -16.5381
            8   O6a O    21.0494  -14.4416
            9   C2a C    16.2033  -18.6648
BOND        8
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     2   5 1
            5     5   6 1
            6     6   7 1
            7     6   8 2
            8     4   9 2